Interferon beta-lb in the treatment of multiple sclerosis

Final outcome of the randomized controlled trial

The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group

Research output: Contribution to journalArticle

1151 Citations (Scopus)

Abstract

Our previously reported multicenter, blinded, randomized, controlled study of two doses of interferon beta-lb (IFNB) in 372 patients demonstrated a reduction in relapse frequency and severity and in MRI activity. We now report the results of the continuation of that study. The median time on study was 46.0 months for the placeboarm, 45.0 months for 1.6 million international units (MIU), and 48.0 months for 8 MIU. IFNB had a persistent beneficial effect on exacerbation rate and MRI burden of disease and was relatively free of long-term side effects. There was a one-third reduction in exacerbation rate in the 8-MIU treatment arm, compared with placebo, in each of 5 years. Serial annual MRI was done in all patients, and 217 of the patients had either a fourth- or fifth-year scan. There was no significant progression of lesion burden in the 8-MIU arm in each successive year compared with baseline (at 4 years, p = 0.917), whereas a highly significant increase in lesion area occurred in the placebo arm (p = 0.0001). Among the 154 noncompleters, there was no systematic bias recognized that favored either treatment arm for the outcome measures of exacerbation rate, disability, or MRI activity. Dropouts in the placebo group had higher exacerbation rates and accumulation of MRI lesion burden than did dropouts in the other treatment arms, which probably reduced the power of the study to demonstrate treatment effects on these measures in the later years of the trial. Neutralizing antibodies to IFNB were detectable in 38% of patients by the third year and were associated with a significant attenuation of treatment effect on exacerbation rate. However, the reduction in exacerbation rate approached 50% in the antibody-negative 8-MIU group. For all patients, both baseline and end point lesion burden significantly correlated with disability. Increase in MRI lesion area was also significantly correlated with increase in disability over the course of the study, validating serial MRI as an outcome measure with clinical relevance. Since the 8-MIU treatment arm had significantly less lesion accumulation by MRI, a reasonable expectation is that IFNB will limit progression of disability. Confirmed disease progression occurred in fewer patients in the high-dose treatment arm (35%) than in the placebo arm (46%) (p = 0.096). These results support but do not establish an effect of IFNB in limiting progression of disability. This study was not originally powered to demonstrate a treatment effect on disease progression. At these levels of disability, more patients or longer follow-up, or both, would be required. Accordingly, additional clinical trials will be necessary to evaluate the role of IFNB in preventing disability.

Original languageEnglish (US)
Pages (from-to)1277-1285
Number of pages9
JournalNeurology
Volume45
Issue number7
StatePublished - 1995

Fingerprint

Interferon-beta
Multiple Sclerosis
Randomized Controlled Trials
Placebos
Therapeutics
Disease Progression
Outcome Assessment (Health Care)
Randomized Controlled Trial
Neutralizing Antibodies
Lesion
Progression
Clinical Trials
Recurrence
Burden
Placebo
Antibodies
Treatment Effects

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

The IFNB Multiple Sclerosis Study Group, & The University of British Columbia MS/MRI Analysis Group (1995). Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology, 45(7), 1277-1285.

Interferon beta-lb in the treatment of multiple sclerosis : Final outcome of the randomized controlled trial. / The IFNB Multiple Sclerosis Study Group; The University of British Columbia MS/MRI Analysis Group.

In: Neurology, Vol. 45, No. 7, 1995, p. 1277-1285.

Research output: Contribution to journalArticle

The IFNB Multiple Sclerosis Study Group & The University of British Columbia MS/MRI Analysis Group 1995, 'Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial', Neurology, vol. 45, no. 7, pp. 1277-1285.
The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group. Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology. 1995;45(7):1277-1285.
The IFNB Multiple Sclerosis Study Group ; The University of British Columbia MS/MRI Analysis Group. / Interferon beta-lb in the treatment of multiple sclerosis : Final outcome of the randomized controlled trial. In: Neurology. 1995 ; Vol. 45, No. 7. pp. 1277-1285.
@article{8b9a48bdaf5047d6843164c13134681b,
title = "Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial",
abstract = "Our previously reported multicenter, blinded, randomized, controlled study of two doses of interferon beta-lb (IFNB) in 372 patients demonstrated a reduction in relapse frequency and severity and in MRI activity. We now report the results of the continuation of that study. The median time on study was 46.0 months for the placeboarm, 45.0 months for 1.6 million international units (MIU), and 48.0 months for 8 MIU. IFNB had a persistent beneficial effect on exacerbation rate and MRI burden of disease and was relatively free of long-term side effects. There was a one-third reduction in exacerbation rate in the 8-MIU treatment arm, compared with placebo, in each of 5 years. Serial annual MRI was done in all patients, and 217 of the patients had either a fourth- or fifth-year scan. There was no significant progression of lesion burden in the 8-MIU arm in each successive year compared with baseline (at 4 years, p = 0.917), whereas a highly significant increase in lesion area occurred in the placebo arm (p = 0.0001). Among the 154 noncompleters, there was no systematic bias recognized that favored either treatment arm for the outcome measures of exacerbation rate, disability, or MRI activity. Dropouts in the placebo group had higher exacerbation rates and accumulation of MRI lesion burden than did dropouts in the other treatment arms, which probably reduced the power of the study to demonstrate treatment effects on these measures in the later years of the trial. Neutralizing antibodies to IFNB were detectable in 38{\%} of patients by the third year and were associated with a significant attenuation of treatment effect on exacerbation rate. However, the reduction in exacerbation rate approached 50{\%} in the antibody-negative 8-MIU group. For all patients, both baseline and end point lesion burden significantly correlated with disability. Increase in MRI lesion area was also significantly correlated with increase in disability over the course of the study, validating serial MRI as an outcome measure with clinical relevance. Since the 8-MIU treatment arm had significantly less lesion accumulation by MRI, a reasonable expectation is that IFNB will limit progression of disability. Confirmed disease progression occurred in fewer patients in the high-dose treatment arm (35{\%}) than in the placebo arm (46{\%}) (p = 0.096). These results support but do not establish an effect of IFNB in limiting progression of disability. This study was not originally powered to demonstrate a treatment effect on disease progression. At these levels of disability, more patients or longer follow-up, or both, would be required. Accordingly, additional clinical trials will be necessary to evaluate the role of IFNB in preventing disability.",
author = "{The IFNB Multiple Sclerosis Study Group} and {The University of British Columbia MS/MRI Analysis Group} and Pierre Duquette and Lielte Despault and L. Knobler and Lublin, {Fred D.} and Leith Kelley and Francis, {Gorden S.} and Mark Freedman and Yves Lapierre and Stanley Hum and Greenstein, {Jeffrey I.} and Bibhuti Mishra and Nina Delillio and John Whitaker and Beverly Layton and Sibley, {William A.} and Joan Laguna and John Krikawa and Paty, {Donald W.} and Oger, {Joel J.} and Kastrukoff, {Lorne F.} and Wendy Morrison and Jill Nelson and Douglas Goodin and Massa, {Steven M.} and Elena Gutteridge and Pierre Duquette and Arnason, {Barry G W} and Auertan Noronha and Reder, {Anthony T.} and Roberta Martia and Ebers, {George C.} and Rice, {George P A} and Jane Lesaux and Johnson, {Kenneth P.} and Panitch, {Hillel S.} and Bever, {Christopher T.} and Li, {David K B} and Paty, {Donald W.} and Tanton, {E. L.} and Zhao, {Guo Jun} and Borys Flak and Andrew Riddehough and Keith Cover and Brenda Rhodes and Andrea Cook and Karen Smith and Lesley Costley and Sylvia Renneberg and Trudy Shaw and Weinshenker, {Brian G}",
year = "1995",
language = "English (US)",
volume = "45",
pages = "1277--1285",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Interferon beta-lb in the treatment of multiple sclerosis

T2 - Final outcome of the randomized controlled trial

AU - The IFNB Multiple Sclerosis Study Group

AU - The University of British Columbia MS/MRI Analysis Group

AU - Duquette, Pierre

AU - Despault, Lielte

AU - Knobler, L.

AU - Lublin, Fred D.

AU - Kelley, Leith

AU - Francis, Gorden S.

AU - Freedman, Mark

AU - Lapierre, Yves

AU - Hum, Stanley

AU - Greenstein, Jeffrey I.

AU - Mishra, Bibhuti

AU - Delillio, Nina

AU - Whitaker, John

AU - Layton, Beverly

AU - Sibley, William A.

AU - Laguna, Joan

AU - Krikawa, John

AU - Paty, Donald W.

AU - Oger, Joel J.

AU - Kastrukoff, Lorne F.

AU - Morrison, Wendy

AU - Nelson, Jill

AU - Goodin, Douglas

AU - Massa, Steven M.

AU - Gutteridge, Elena

AU - Duquette, Pierre

AU - Arnason, Barry G W

AU - Noronha, Auertan

AU - Reder, Anthony T.

AU - Martia, Roberta

AU - Ebers, George C.

AU - Rice, George P A

AU - Lesaux, Jane

AU - Johnson, Kenneth P.

AU - Panitch, Hillel S.

AU - Bever, Christopher T.

AU - Li, David K B

AU - Paty, Donald W.

AU - Tanton, E. L.

AU - Zhao, Guo Jun

AU - Flak, Borys

AU - Riddehough, Andrew

AU - Cover, Keith

AU - Rhodes, Brenda

AU - Cook, Andrea

AU - Smith, Karen

AU - Costley, Lesley

AU - Renneberg, Sylvia

AU - Shaw, Trudy

AU - Weinshenker, Brian G

PY - 1995

Y1 - 1995

N2 - Our previously reported multicenter, blinded, randomized, controlled study of two doses of interferon beta-lb (IFNB) in 372 patients demonstrated a reduction in relapse frequency and severity and in MRI activity. We now report the results of the continuation of that study. The median time on study was 46.0 months for the placeboarm, 45.0 months for 1.6 million international units (MIU), and 48.0 months for 8 MIU. IFNB had a persistent beneficial effect on exacerbation rate and MRI burden of disease and was relatively free of long-term side effects. There was a one-third reduction in exacerbation rate in the 8-MIU treatment arm, compared with placebo, in each of 5 years. Serial annual MRI was done in all patients, and 217 of the patients had either a fourth- or fifth-year scan. There was no significant progression of lesion burden in the 8-MIU arm in each successive year compared with baseline (at 4 years, p = 0.917), whereas a highly significant increase in lesion area occurred in the placebo arm (p = 0.0001). Among the 154 noncompleters, there was no systematic bias recognized that favored either treatment arm for the outcome measures of exacerbation rate, disability, or MRI activity. Dropouts in the placebo group had higher exacerbation rates and accumulation of MRI lesion burden than did dropouts in the other treatment arms, which probably reduced the power of the study to demonstrate treatment effects on these measures in the later years of the trial. Neutralizing antibodies to IFNB were detectable in 38% of patients by the third year and were associated with a significant attenuation of treatment effect on exacerbation rate. However, the reduction in exacerbation rate approached 50% in the antibody-negative 8-MIU group. For all patients, both baseline and end point lesion burden significantly correlated with disability. Increase in MRI lesion area was also significantly correlated with increase in disability over the course of the study, validating serial MRI as an outcome measure with clinical relevance. Since the 8-MIU treatment arm had significantly less lesion accumulation by MRI, a reasonable expectation is that IFNB will limit progression of disability. Confirmed disease progression occurred in fewer patients in the high-dose treatment arm (35%) than in the placebo arm (46%) (p = 0.096). These results support but do not establish an effect of IFNB in limiting progression of disability. This study was not originally powered to demonstrate a treatment effect on disease progression. At these levels of disability, more patients or longer follow-up, or both, would be required. Accordingly, additional clinical trials will be necessary to evaluate the role of IFNB in preventing disability.

AB - Our previously reported multicenter, blinded, randomized, controlled study of two doses of interferon beta-lb (IFNB) in 372 patients demonstrated a reduction in relapse frequency and severity and in MRI activity. We now report the results of the continuation of that study. The median time on study was 46.0 months for the placeboarm, 45.0 months for 1.6 million international units (MIU), and 48.0 months for 8 MIU. IFNB had a persistent beneficial effect on exacerbation rate and MRI burden of disease and was relatively free of long-term side effects. There was a one-third reduction in exacerbation rate in the 8-MIU treatment arm, compared with placebo, in each of 5 years. Serial annual MRI was done in all patients, and 217 of the patients had either a fourth- or fifth-year scan. There was no significant progression of lesion burden in the 8-MIU arm in each successive year compared with baseline (at 4 years, p = 0.917), whereas a highly significant increase in lesion area occurred in the placebo arm (p = 0.0001). Among the 154 noncompleters, there was no systematic bias recognized that favored either treatment arm for the outcome measures of exacerbation rate, disability, or MRI activity. Dropouts in the placebo group had higher exacerbation rates and accumulation of MRI lesion burden than did dropouts in the other treatment arms, which probably reduced the power of the study to demonstrate treatment effects on these measures in the later years of the trial. Neutralizing antibodies to IFNB were detectable in 38% of patients by the third year and were associated with a significant attenuation of treatment effect on exacerbation rate. However, the reduction in exacerbation rate approached 50% in the antibody-negative 8-MIU group. For all patients, both baseline and end point lesion burden significantly correlated with disability. Increase in MRI lesion area was also significantly correlated with increase in disability over the course of the study, validating serial MRI as an outcome measure with clinical relevance. Since the 8-MIU treatment arm had significantly less lesion accumulation by MRI, a reasonable expectation is that IFNB will limit progression of disability. Confirmed disease progression occurred in fewer patients in the high-dose treatment arm (35%) than in the placebo arm (46%) (p = 0.096). These results support but do not establish an effect of IFNB in limiting progression of disability. This study was not originally powered to demonstrate a treatment effect on disease progression. At these levels of disability, more patients or longer follow-up, or both, would be required. Accordingly, additional clinical trials will be necessary to evaluate the role of IFNB in preventing disability.

UR - http://www.scopus.com/inward/record.url?scp=0029161628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029161628&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 1277

EP - 1285

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -